Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- LVEF
研究概览
简要总结
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
详细描述
Transtuzumab based chemo-immunotherapy is commonly administered to patients diagnosed with early stage HER-2 expressing breast cancer, because it decreases the risk of relapse.
Transtuzumab affects cardiac function and potential benefits in decreasing cancer recurrence have to be balanced against short and long term toxicity.
We have previously identified a high prevalence of metabolic syndrome and type II diabetes mellitus in our patients with breast cancer. These patients may be particularly susceptible to cardiotoxic effects of transtuzumab based therapy.
Aim of this study is to assess the changes in the cardiac function of women who are undergoing transtuzumab based therapy for early stage breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Stage 1,2,3 breast cancer
排除标准
- •Stage 4 cancer
结局指标
主要结局
LVEF
时间窗: Baseline (prior to therapy), at 3-6 months (mid-therapy), and at 1 year (end of therapy)
LV ejection fraction
次要结局
- Number of Participants Hospitalized for Cardiac Issues.(1 year)
研究者
Sumit Gaur
MD
Texas Tech University Health Sciences Center, El Paso